Metallographic Laboratory opens on Campus of University of Warwick
with over 600 staff and a strong relation with over 1000 global companies, offering support to over 1800 SMEs through dedicated programmes. Part of WMG’s Materials Engineering Centre at the University of Warwick (UK) campus, Buehler’s new Solutions Centre aims to support academic and industrial research on various technologies ranging from additive manufacturing, energy storage, machining and processing of metallic and composite materials to joining technologies.
The recently opened Solutions Centre on the campus of the University of Warwick/UK is equipped with the latest systems for sample preparation and material characterisation. © Buehler
Buehler ITW Test & Measurement, a leading manufacturer of instruments, consumables and accessories for metallography and materials analysis, has opened a new European Solutions Centre in a collaborative venture with Warwick Manufacturing Group (WMG)
The new laboratory is equipped with latest metallographic sample preparation equipment, including several abrasive and precision sectioning machines, high-end grinder-polishers and a spectral analysis system for chemical characterisation of materials. Available equipment also includes the company’s latest hardness testers in varying degrees of automation and testing capabilities, and Nikon optical microscopes interfaced with Buehler’s own image analysis software for ideal metallographic analysis.
Dr Evans Mogire, European Technical and Laboratory Manager at Buehler, commented: “The new Solutions Centre allows us to better address complex customer applications and/or technical requests
relating to metallography and provides exceptional facilities for conducting and hosting seminars in the metallographic sector. The collaboration with WMG is a win-win relationship, offering both resident material scientists and Buehler access to latest characterisation technologies for metallic, polymer, ceramic and composite materials.”
Paul Johnson, Technical Services Manager at WMG, added: “This well-equipped microscopy, metallographic and materials preparation laboratory provides a valuable resource for the entire group. It offers us the opportunity to work side by side with a leading developer, producer and supplier providing us with leading-edge, perfectly maintained metallographic preparation and characterisation equipment, whilst Buehler can benefi t by working with the very latest materials that we are developing and gain valuable insights for the further development of its product range.”
More information online:
ilmt.co/PL/KJpe 49523pr@reply-direct.com
European Lead Factory Secures IMI Funding
The European Lead Factory (ELF), a public-private partnership to transform drug targets into new medicines, has secured a total project budget of €36.5 million under the second framework of the Innovative Medicines Initiative (IMI). Over the next 5 years, 20 partners in 7 countries, including the University of Dundee, will be involved with the ELF brand project in the new ESCulab (European Screening Centre: unique library for attractive biology).
The project partners will have access to large high-quality compound libraries derived from the pharmaceutical industry and the Public Compound Collection and Europe’s leading screening facility, alongside the innovative targets held by academic organisations. This provides an ideal platform to translate early-stage fundamental biological research into credible and investable starting points for drug discovery campaigns.
The National Phenotypic Screening Centre (NPSC), based within the School of Life Sciences at the University of Dundee will bring expertise in developing and screening complex biological assays using “high content” phenomics technology to the initiative.
Dr Paul Andrews, Director of Operations at the NPSC, said, “By employing quantitative microscopy or fl ow cytometry to measure a range of disease-
relevant responses in cells, our approach has the potential to accelerate the development of safer and more effective medicines.”
Dundee will receive around €1.3 million for the NPSC’s contribution over the course of the project.
Jon de Vlieger, coordinator of the ESCulab consortium at Lygature, commented: “It’s truly exciting to continue the onboarding of new and innovative proposals for screening and provide high quality starting points for drug discovery to academics and SMEs throughout Europe. In an effort to broaden our scope we are not only looking for target-based approaches, but now also enable phenotypic screens.”
The successful concept of the European Lead Factory has already encouraged additional private partners to join. The ESCulab Project welcomes the two pharmaceutical companies Servier and Grünenthal as well as the Medicines for Malaria Venture (MMV), the leading product development partnership in the fi eld of antimalarial drug research and development.
49528pr@reply-direct.com Pascal Neuville
Acquisitions a Key Asset for Integrated Cancer Care Solutions
The acquisition of Endocare, a provider of hardware and software solutions supporting cryoablation and microwave ablation and Hangzhou, China-based Alicon, a leader in embolic therapy for treating liver cancer in China, has helped cement Varian’s position in the high-value interventional oncology segment, which is expected to grow from approximately $860 million in 2019 to over $1 billion in 2022 [1]. Varian will leverage the existing product portfolios of both companies as well as the active R&D programs powered by teams in Austin and Hangzhou. “Together, our acquisitions of Endocare and Alicon are an important step in Varian’s long-term strategy to become a global leader in multidisciplinary, integrated cancer solutions,” said Dow Wilson, President and Chief Executive Offi cer of Varian. “We are confi dent that the portfolio of products and both companies’ dynamic R&D pipelines will unlock new growth for Varian and expand our clinical partners’ treatment options in the years to come. Varian is uniquely positioned to create an interventional oncology platform that combines software and services for treatment planning with advanced interventional treatment delivery.”
“We are excited about the opportunity to join Varian,” said David Chen, Chief Executive Offi cer of Endocare and Alicon. “Endocare, Alicon and Varian share a common goal of delivering innovative cancer care solutions and this transaction will advance a united ability to develop the solutions necessary to achieve that goal. On a personal note, I am deeply proud of the products the Endocare and Alicon teams have developed and I look forward to expanding our global patient impact together with Varian.” Varian is said to be fi nancing the $185 million purchase price using cash and proceeds from borrowings. Endocare and Alicon generated combined revenue of $30 million in calendar 2018. Varian expects the aggregate of these transactions to have an immaterial impact on fi scal year 2019 fi nancial results and the combined interventional oncology platform to be accretive to GAAP and Non-GAAP earnings per share in fi scal 2020.
1. Kaiser Associates
49488pr@reply-direct.com
A €3.5million ($3.9million) investment from existing shareholder Seventure Partners, to accelerate the development of its programmes targeting membrane receptors in Central Nervous System (CNS) disorders; oncology/immuno-oncology and rare diseases, has been announced by Domain Therapeutics
The company successfully executed on the three pillars of its business strategy in 2018, thanks to a multitarget collaboration agreement with Boehringer Ingelheim, a license granted on the bioSens-All™ technology platform to BMS and the acquisition by Lundbeck of Prexton Therapeutics, one of the asset-centric companies developing Strasbourg-based Domain’s programs.
“Seventure Partners is proud to be a strategic fi nancial partner for Domain Therapeutics, a company with validated breakthrough technologies,” said Sébastien Groyer, Partner, Seventure Partners. “Since our last investment in the company, Pascal Neuville and his team have signifi cantly expanded the business and increased the value of the company.”
“With Domain being a profi table biotech, the support of Seventure aims at kick-starting our acceleration phase,” said Pascal Neuville, CEO of Domain Therapeutics. “This recognition by a major shareholder of our capacity to create value is a positive signal for future investors and will pave the way for a signifi cant investment aimed at further speeding up company growth.”
49508pr@reply-direct.com
Injection for New Drug Candidate Programmes
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60
